Moteur de recherche d’entreprises européennes
Financement de l’UE (150 000 €) : Système MicroScale intégrant des organoïdes cancéreux spécifiques au patient dans un microenvironnement tumoral 3D pour la prédiction de la thérapie Hor14/04/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Système MicroScale intégrant des organoïdes cancéreux spécifiques au patient dans un microenvironnement tumoral 3D pour la prédiction de la thérapie
Cancer remains a leading global cause of death, with incidence projected to increase significantly by 2050. Despite advances in detection and treatment, there is an urgent need for more effective and personalized therapies. Personalized medicine (PM) is emerging as the future of cancer care, using 3D patient-specific models to replicate the tumors complexity. Current in vitro models struggle to accurately mimic the tumor microenvironment (TME), including the extracellular matrix (ECM) and stromal interactions, which are critical to tumor progression and therapy response. SPOTTED aims to address these limitations by developing patient-derived (PD) in vitro models integrated into a microfluidic device, by exploiting patient-derived organoids (PDOs) from bioptic tissues from the Biobanca di Ricerca of the University Hospital of Padua. The first vertical case study is on pancreatic cancer (PC), projected to become the second deadliest type of solid tumor by 2040. Our SPOTTED platform will use PDOs and PD-ECM hydrogels to reconstruct a realistic 3D model of PC, incorporating stromal and immune cells. By replicating the TME, SPOTTED enables precise drug screening and therapeutic testing in a highly controlled and automated environment. Its design allows for real-time monitoring and analysis, while the platform’s versatility supports scalable, reproducible experiments tailored to individual patients. SPOTTED, with its customizable, patient-specific approach, aims to bridge the gap between laboratory research and clinical application, paving the way for more effective, tailored therapies for PC and other solid tumors, with the potential to revolutionize personalized cancer treatment.
| Universita Degli Studi Di Padova | 150 000 € |
https://cordis.europa.eu/project/id/101213265
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Universita' Degli Studi Di Padova, Padoue, Italie.